Rifampin is safe for treatment of pruritus due to chronic cholestasis: A Meta-analysis of prospective randomized-controlled trials

Liver International

Volumn 26, Issue 8, 2006, Pages 943-948

  Khurana, Sandeep ^a   Singh, Pankaj ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Cholestasis; Itching; Liver disease; Pruritus; Rifampicin; Rifampin

Indexed keywords

COLESTYRAMINE; PHENOBARBITAL; PLACEBO; RIFAMPICIN;

ALLERGIC REACTION; ANOREXIA; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HEMOLYTIC ANEMIA; HUMAN; INTRAHEPATIC CHOLESTASIS; KIDNEY FAILURE; LIVER TOXICITY; MANTEL HAENSZEL TEST; MEDICAL LITERATURE; META ANALYSIS; NAUSEA; NULL HYPOTHESIS; PRURITUS; REFERENCE VALUE; RISK ASSESSMENT; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHOLESTASIS; CHRONIC DISEASE; CROSS-OVER STUDIES; HUMANS; PROSPECTIVE STUDIES; PRURITUS; RIFAMPIN;

EID: 33748293049     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01326.x     Document Type: Article

References (40)

1. Sherlock S, Scheuer P J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289 (13): 674-8.
2. Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F W. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-70.
3. Carey J B, Williams G. Relief of pruritus of jaundice with bile acid sequestering resin. JAMA 1961; 176: 432-35.
4. Bloomer, J R, Boyer J L. Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975; 82: 310-17.
5. Duncan J S, Kennedy H J, Triger D R. Treatment of pruritus due to chronic obstructive liver disease. Br Med J Clin Res Ed 1984; 289 (6436): 22.
6. Alva J, Iber F L. Relief of pruritus of jaundice with methandrostenolone and speculation of the nature of pruritus in liver disease. Am J Med Sci 1965; 250: 60-5.
7. Summerfield J A. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980; 10 (2): 180-3.
8. Serge E. Cholestasis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 7th edn. Philadelphia: Lippincott-Raven, 1999; 611-31.
9. Scheuer P, Ladel S, Summerfield J, et al. Rifampicin hepatitis. Lancet 1974; 421-5.
10. Lees A W, Allan G W, Smith J, et al. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182-90.
11. Hollins P J, Simmons A V. Jaundice associated with rifampicin. Tubercle 1970; 51: 328-32.
12. Meade M O, Richardson W S. Selecting and appraising studies for a systematic review. Ann Intern Med 1997; 127: 531-7.
13. Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th edn. Rahway, NJ: Merck & Co, 1989.
14. Poynard T. Evaluation of the methodological quality of randomized therapeutic trials. Presse Medicale 1988; 17 (7): 315-8.
15. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986; 42: 311-23.
16. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
17. Ghent C N, Carruthers S G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94 (2): 488-93.
18. Cynamon H A, Andres J M, Iafrate R P. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98 (4): 1013-6.
19. Woolf G M, Reynolds T B. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990; 12 (2): 174-7.
20. Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Digve Dis Sci 1991; 36 (2): 216-20.
21. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 574-76.
22. Ghent C N, Carruthers S G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. (Abstract 33). Hepatology 1986; 6 (5): 1113.
23. Woolf, G M Reynolds T B. Treatment of pruritus in chronic liver disease with rifampin. (Abstract 621). Hepatology 1989; 10 (4): 724.
24. Hoensch H P, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus E E. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985; 28 (4): 475-7.
25. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102 (6): 2077-80.
26. Gregorio G V, Ball C S, Mowat A P, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Childhood 1993; 69 (1): 141-3.
27. Cancado E L, Leitao R M, Carrilho F J, Laudanna A A. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 1998; 93 (9): 1510-7.
28. Price T J, Patterson W K, Olver I N. Rifampicin as treatment for pruritus in malignant cholestasis. Support Care Cancer 1998; 6 (6): 533-5.
29. Yerushalmi B, Sokol R J, Narkewicz M R, Smith D, Karrer F M. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999; 29 (4): 442-7.
30. O'Brien M D, Jorgensen R A, DeSotel C K, et al. The natural history of pruritus associated with primary biliary cirrhosis. Gastroenterology 1994; 106 (4): A953.
31. Souto E, Lindor K D, Jorgensen R A, DeSotel C K, Hofmann A J Keach J. Long-term rifampin use in patients with primary biliary cirrhosis and pruritus. Gastroenterology 1999; 116 (4): A1279.
32. Curtin F, Elbourne D, Altman D G., Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Stat Med 2002; 21 (15): 2161-73.
33. Curtin F, Elbourne D, Altman D G. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Stat Med 2002; 21 (15): 2145-59.
34. Curtin F, Altman D G, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statist Med 2002; 21 (15): 2131-44.
35. Prince M I, Burt A D, Jones D E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50 (3): 436-9.
36. Ghent C N. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gatroenterol 1987; 82: 117-8.
37. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983; (5, Suppl. 3): S428-32.
38. Miguet J P, Mavier P, Soussy C J Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology 1977; 72 (5, Part 1): 924-6.
39. Thornton J R, Losowsky M S. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297: 1501-4.
40. Bergasa N V, Talbot T L, Alling D W, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-9.